伊马替尼在妇科肿瘤中的研究进展  

Research Progress on Imatinib in Gynecological Tumors

作　　者：冯磊[1] 田晓予[1] 

机构地区：[1]河南科技大学第一附属医院妇产科,河南洛阳471003

出　　处：《医学综述》2010年第13期1967-1970,共4页Medical Recapitulate

基　　金：洛阳市科技攻关项目(0801059A)

摘　　要：小分子酪氨酸激酶抑制剂伊马替尼是首次研发的针对慢性粒细胞白血病的分子靶向治疗药物,因其临床疗效好、专一性强、不良反应小等优点,成为最有前景的抗肿瘤药物之一。近年来,伊马替尼成为研究的热点,伊马替尼应用于妇科肿瘤的Ⅱ期临床研究也较多。许多妇科肿瘤(如卵巢癌、宫颈癌等)高表达伊马替尼的靶向受体c-kit和血小板衍生生长因子受体,现就其在妇科肿瘤中的研究进展予以综述。Imatinib mesylate is a small molecule tyrosine kinase inhibitor specifically against chronic my- elogenous leukemia. Because of its good clinical efficacy,specificity and minimal side effects,it has become one of the most promising anticancer drugs. In recent years,imatinib has become a hot spot of research. Studies have shown that many gynecological tumors,such as ovarian cancer and cervical cancer,express imatinib targeting receptor c-kit and platelet derived growth factor receptor. Imatinib is widely used in the clinical studies of gynecological tumors. This paper reviews the research of imatinib in gynecologic tumors.

关 键 词：妇科肿瘤 伊马替尼 血小板源衍生生长因子受体 C-KIT 

分 类 号：R737.3[医药卫生—肿瘤] R730.5[医药卫生—临床医学]